Sacituzumab tirumotecan plus QL1706 for recurrent or metastatic cervical cancer

A Single-arm, Multicenter, Phase II Study of Sacituzumab Tirumotecan (Sac-TMT/SKB264) in Combination With QL1706 for Recurrent or Metastatic Cervical Cancer

This study will test whether combining sacituzumab tirumotecan (a TROP2-targeted antibody‑drug conjugate) with QL1706 (a dual PD‑1/CTLA‑4 antibody) helps people with recurrent or metastatic cervical cancer who have already received platinum therapy.

Quick facts

• Phase: Phase 2
• Study type: Interventional
• Enrollment: 89 (estimated)
• Ages: 18 Years and up
• Sex: Female
• Sponsor: Fujian Cancer Hospital (Government)
• Drugs / interventions: chemotherapy, immunotherapy, Sacituzumab
• Locations: 14 sites (Fuzhou, Fujian and 13 other locations)
• Trial ID: NCT07256236 on ClinicalTrials.gov

What this trial studies

This is a multicenter, single-arm Phase II trial testing the combination of sacituzumab tirumotecan (SKB264) and QL1706 in patients with recurrent or metastatic cervical cancer after prior platinum therapy. Patients are enrolled into two cohorts by tumor histology (squamous and non-squamous) and will receive the study drugs with regular safety and radiologic response assessments. The trial will measure objective response rate and safety outcomes to determine antitumor activity and tolerability. The rationale is that TROP2 is frequently overexpressed in cervical cancer and prior data show promising responses when a TROP2-directed ADC is combined with PD-1 blockade.

Who should consider this trial

Good fit: Adult women (≥18 years) with histologically confirmed recurrent or metastatic cervical cancer (squamous, adenocarcinoma, adenosquamous, or other types) who are not candidates for curative therapy and who have progressed on or are intolerant to at least one prior platinum-based regimen are ideal candidates.

Not a fit: Patients with early-stage disease who are eligible for curative surgery or radiotherapy, those who have not received prior platinum therapy as required, or those with contraindications to ADCs or immune checkpoint inhibitors are unlikely to benefit from this protocol.

Why it matters

Potential benefit: If successful, the combination could produce higher response rates and longer disease control than current second-line options for recurrent or metastatic cervical cancer.

How similar studies have performed: Related approaches have shown encouraging signals—QL1706 is approved in China for second-line cervical cancer and a TROP2-directed ADC plus PD-1 therapy produced a 57.9% ORR in a prior phase II study—though the specific SKB264 plus QL1706 combination is not yet proven.

Eligibility criteria

Inclusion Criteria:

* Female, aged ≥18 years at the time of signing the informed consent form;
* Diagnosed with recurrent or metastatic cervical cancer \[pathological types include squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma, etc., with pathological report provided\], and not suitable for radical treatments such as surgery or radiotherapy. Patients will be divided into the following two cohorts based on pathological type:

  * Cohort 1: Cervical squamous cell carcinoma;
  * Cohort 2: Cervical non-squamous carcinoma (including adenocarcinoma or adenosquamous carcinoma, and other types of cervical cancer)
* Have experienced failure of at least one prior line of platinum-based standard therapy or intolerance to platinum-based drugs in the recurrent or metastatic setting, or have experienced radiologically confirmed disease progression during or within 6 months after completion (≥4 cycles) of platinum-based neoadjuvant or adjuvant chemotherapy. Specific requirements are as follows:

  (a) Failure of first-line platinum-based standard therapy: meeting any one of the following criteria: i. Radiologically confirmed disease progression during treatment; ii. Radiologically confirmed disease progression after completion of treatment, provided the patient had a response (Complete Response (CR)/Partial Response (PR)/Stable Disease (SD)) and received ≥4 cycles of treatment; (b) Investigator's judgment that the subject is intolerant to platinum-based drugs; (c) Radiologically confirmed disease progression during or within 6 months after completion (≥4 cycles) of platinum-based neoadjuvant or adjuvant chemotherapy. Weekly chemotherapy administered concurrently with radiotherapy for sensitization purposes should not be counted as chemotherapy cycles;
* According to RECIST (v1.1) criteria, at least one measurable lesion (non-lymph node lesion with longest diameter ≥10 mm, or lymph node lesion with short diameter ≥15 mm). Lesions previously irradiated should not be selected as target lesions; unless there are no other measurable lesions available, in which case a previously irradiated measurable lesion that has shown confirmed progression radiologically may be selected as a target lesion. Subjects with only skin lesions or bone lesions are not eligible;
* Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1 within 7 days prior to dosing;
* Expected survival period ≥12 weeks;
* Subjects must have recovered from all toxicities resulting from prior therapy (i.e., improved to Grade 0 or 1, or to the level specified in the eligibility criteria), except for toxicities not considered a safety risk (such as alopecia, vitiligo, and other asymptomatic laboratory abnormalities). Subjects with ≤ Grade 2 neuropathy will be evaluated on a case-by-case basis in consultation with the investigator;
* Adequate organ and bone marrow function (without transfusion, recombinant human thrombopoietin, or colony-stimulating factor therapy within 2 weeks prior to dosing), defined as follows:

  1. Neutrophil count (NEUT#) ≥1.5×10⁹/L; Platelets (PLT) ≥100×10⁹/L; Hemoglobin ≥90 g/L;
  2. Liver function: Aspartate aminotransferase (AST) and Alanine aminotransferase (ALT) ≤2.5 × ULN; for subjects with baseline liver metastases, ALT and AST ≤5 × ULN; Albumin ≥30 g/L; Total bilirubin (TBIL) ≤1.5 × ULN;
  3. Renal function: Creatinine clearance (Ccr) ≥50 ml/min (calculated using the standard Cockcroft-Gault formula); Urine protein ≤1+; if urine protein ≥2+, then 24-hour urine protein quantification must be ≤1.0 g;
  4. Coagulation function: International Normalized Ratio (INR), Activated Partial Thromboplastin Time (APTT), and Prothrombin Time (PT) ≤1.5 × ULN;
  5. Cardiac left ventricular ejection fraction (LVEF) ≥50%.
* For female subjects of childbearing potential, must agree to use effective medical contraception measures from the time of signing the informed consent form until 6 months after the last dose;
* The subject voluntarily joins this study, signs the informed consent form, and is able to comply with the visits and related procedures stipulated in the protocol.

Exclusion Criteria:

* Subjects who have had a known additional malignancy that is progressing or has required active treatment within the past 5 years. Exceptions include basal cell carcinoma of the skin, squamous cell carcinoma of the skin, etc., that has undergone potentially curative therapy.
* Subjects with known leptomeningeal metastasis, brainstem metastasis, spinal cord metastasis and/or compression, or other active central nervous system (CNS) metastases. Subjects with brain metastases treated with local therapy may be enrolled if they meet the following criteria: clinically stable for at least 4 weeks, and no requirement for steroid treatment for at least 14 days prior to the first dose of study drug.
* Subjects with clinically significant cardiovascular diseases, such as: a) Presence of severe or uncontrolled cardiac disease or clinical symptoms requiring treatment within 6 months prior to the first study dose, including: congestive heart failure classified as New York Heart Association (NYHA) Class III or IV, unstable angina pectoris uncontrolled by medication, severe arrhythmia requiring drug treatment (except for atrial fibrillation or paroxysmal supraventricular tachycardia), and myocardial infarction; b) Previous history of myocarditis or cardiomyopathy; c) QTc interval \> 480 ms based on baseline measurement.
* Subjects with severe and/or uncontrolled concurrent diseases, such as decompensated liver cirrhosis, nephrotic syndrome, uncontrolled hypertension or severe hypertension, clinically symptomatic pleural effusion, pericardial effusion, or ascites requiring repeated drainage.
* Subjects diagnosed with active Hepatitis B or Hepatitis C.
* Subjects with known poorly controlled human immunodeficiency virus (HIV) infection, including HIV infection with a history of Kaposi's sarcoma and/or multicentric Castleman's disease.
* Subjects with known active tuberculosis.
* Subjects with a history of severe dry eye syndrome, meibomian gland dysfunction, blepharitis, or corneal diseases that affect timely corneal healing.
* Subjects with a known prior history of fistula of the female reproductive tract (e.g., vesicovaginal fistula, urethrovaginal fistula, vesicocervical fistula, etc.); subjects may be enrolled if the perforation or fistula has been treated with diversion surgery, resection, or repair, and the disease is considered by the investigator to have recovered or resolved.
* Subjects who have undergone major surgery (as defined by the investigator) within 30 days prior to the first dose of study treatment or have not recovered from prior surgery.
* Subjects with known allergy or hypersensitivity to the study drug or excipients; history of severe hypersensitivity to monoclonal antibodies.
* Subjects with a history of interstitial lung disease (ILD), or history of non-infectious pneumonitis requiring steroid treatment, or current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging during screening.
* Subjects with a history of allogeneic tissue/organ transplantation.
* Subjects with autoimmune disease that required systemic treatment within the past 2 years or requires immunosuppressive therapy during the study period. Subjects with controlled Type 1 diabetes, thyroiditis with normal thyroid function, hypothyroidism controlled well with hormone replacement therapy (HRT), or skin diseases not requiring systemic treatment (e.g., vitiligo, psoriasis) can be enrolled.
* Subjects who have previously received TROP2-targeted therapy, or any drug containing a topoisomerase I inhibitor, including antibody-drug conjugate (ADC) therapy.
* Subjects who have previously used any experimental anticancer vaccine, or any drug targeting T-cell co-stimulation pathways.
* Administration of a live vaccine within 30 days prior to the first dose of study treatment, or planned administration of a live vaccine during the study.
* Requirement for strong inhibitors or inducers of cytochrome P450 3A4 (CYP3A4) within 2 weeks prior to the first dose of study treatment or during the study.
* Received any chemotherapy, radiotherapy, immunotherapy, or biologic therapy within 4 weeks prior to the first dose of study treatment; received small molecule tyrosine kinase inhibitors (TKIs), antitumor hormone therapy, systemic immunostimulants (including but not limited to interferon, IL-2), or Chinese herbal patent medicines with approved anti-tumor indications within 2 weeks prior to the first dose of study treatment.
* Received palliative radiotherapy to known metastatic sites within 2 weeks prior to the first dose of study treatment.
* Received systemic anti-infection therapy within 1 week prior to the first dose of study treatment.
* Any condition requiring systemic corticosteroid therapy (at doses \>10 mg/day prednisolone or equivalent dose of similar drugs) or other immunosuppressive therapy within 14 days prior to the first dose of study treatment. However, subjects using intranasal, inhaled, topical, or local corticosteroid injections (e.g., intra-articular injection), or using corticosteroids as premedication for hypersensitivity reactions can be enrolled.
* Women who are pregnant or breastfeeding.
* Any condition that, in the investigator's judgment, interferes with the evaluation of the study drug, the subject's safety, or the interpretation of study results, or any other circumstance that the investigator considers inappropriate for participation in this study.

Where this trial is running

Fuzhou, Fujian and 13 other locations

• Fujian Cancer Hospital — Fuzhou, Fujian, China (Recruiting)
• Fujian Medical University Affiliated Second Hospital — Fuzhou, Fujian, China (Not_yet_recruiting)
• Zhangzhou Affiliated Hospital of Fujian Medical University — Zhangzhou, Fujian, China (Recruiting)
• Zhujiang Hospital of Southern Medical University — Guangzhou, Guangdong, China (Not_yet_recruiting)
• Guangxi Medical University Cancer Hospital — Nanning, Guangxi, China (Not_yet_recruiting)
• The Affiliated Hospital of Inner Mongolia Medical University — Hohhot, Inner Mongolia, China (Not_yet_recruiting)
• The Second Hospital of Dalian Medical University — Dalian, Liaoning, China (Not_yet_recruiting)
• Qilu Hospital of Shandong University — Jinan, Shandong, China (Not_yet_recruiting)
• The Second Qilu Hospital of Shandong University — Jinan, Shandong, China (Not_yet_recruiting)
• Shandong Provincial Hospital — Jinan, Shandong, China (Not_yet_recruiting)
• Cancer Hospital of Shandong First Medical University — Jinan, Shandong, China (Not_yet_recruiting)
• Affiliated Hospital of Jining Medical University — Jining, Shandong, China (Not_yet_recruiting)
• Qilu Hospital of Shandong University(Qingdao) — Qingdao, Shandong, China (Not_yet_recruiting)
• Shanxi Cancer Hospital — Taiyuan, Shanxi, China (Not_yet_recruiting)

Study contacts

• Study coordinator: Qin Xu, Ph.D

Conditions Cervical Cancer